Patents Assigned to Calgent Biotechnology Co., Ltd.
  • Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
    Patent number: 11919858
    Abstract: The invention relates to compounds of formula (I) with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: March 5, 2024
    Assignee: Calgent Biotechnology Co., Ltd.
    Inventors: Yun Yen, Jing-ping Liou, Shiow-lin Pan
  • Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases
    Patent number: 11833122
    Abstract: The invention relates to the use of a compound of Formula (I) as described herein and its effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: December 5, 2023
    Assignee: Calgent Biotechnology Co., Ltd.
    Inventors: Yun Yen, Jing-ping Liou, Chien Huang Lin
  • Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
    Patent number: 11084786
    Abstract: The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: August 10, 2021
    Assignee: CALGENT BIOTECHNOLOGY CO., LTD.
    Inventors: Yun Yen, Jing-Ping Liou, Shiow-Lin Pan
  • Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
    Patent number: 10745350
    Abstract: The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.
    Type: Grant
    Filed: July 30, 2016
    Date of Patent: August 18, 2020
    Assignee: Calgent Biotechnology Co., Ltd.
    Inventors: Yun Yen, Jing-ping Liou, Shiow-lin Pan